APA (7th ed.) Citation

ZR, L., TL, X., MY, W., LJ, Z., YM, L., BY, Y., . . . Q, Z. (2025). Inactivation of TACC2 epigenetically represses CDKN1A and confers sensitivity to CDK inhibitors. Med (New York, N.Y.), 6(5), 100568. https://doi.org/10.1016/j.medj.2024.12.002

Chicago Style (17th ed.) Citation

ZR, Lin, et al. "Inactivation of TACC2 Epigenetically Represses CDKN1A and Confers Sensitivity to CDK Inhibitors." Med (New York, N.Y.) 6, no. 5 (2025): 100568. https://doi.org/10.1016/j.medj.2024.12.002.

MLA (9th ed.) Citation

ZR, Lin, et al. "Inactivation of TACC2 Epigenetically Represses CDKN1A and Confers Sensitivity to CDK Inhibitors." Med (New York, N.Y.), vol. 6, no. 5, 2025, p. 100568, https://doi.org/10.1016/j.medj.2024.12.002.